Freshfields advised Camurus on its collaboration and license agreement with Eli Lilly. The agreement grants Lilly exclusive, worldwide rights to the research, development, manufacture and commercialization of long-acting incretin products for cardiometabolic health based on Camurus’ FluidCrystal technology. The agreement comprises up to four Lilly proprietary drug compounds.*

In return for granting Lilly the license to use the FluidCrystal technology for the selected incretin drug compounds for cardiometabolic health, Camurus is eligible to receive up to $290 million in upfront, development, and regulatory milestone payments as well as $580 million in sales-based milestone payments and tiered mid-single digit royalties on global net product sales.

The Freshfields team was led by partners Adam Golden and Jeff Jay and included associate Juliana Zhang.

*Selected from dual GIP and GLP-1 receptor agonists, triple GIP, glucagon and GLP-1 receptor agonists, and an option to include amylin receptor agonists.